Introducing Systagenix Wound Management
Introducing Systagenix Wound Management, a new global force in advanced wound care
Systagenix Wound Management, a new portfolio company created by one equity partners1, launched today with the intent of establishing a new global force in advanced wound care, committed to providing innovative products that help enhance patients’ quality of life.
Systagenix Wound Management, formerly the Professional Wound Care Business of Ethicon, Inc2., a Johnson & Johnson company, is focused on achieving further success, whilst building on its internationally renowned advanced and general wound care product portfolios. These include brands such as PROMOGRAN™ Matrix Wound Dressing, TIELLE™ Hydropolymer Dressing and REGRANEX™ (becaplermin) Gel 0.01%, a prescription treatment for lower extremity diabetic ulcers.
Systagenix Wound Management's newly appointed senior management team headed up by Executive Chairman Chris Fashek and CEO Steve Atkinson are setting the agenda for change and will be driving a new energy and focus into the business. The aim is to make Systagenix Wound Management a leading global provider of innovative wound care solutions, meeting the demands and needs of its customers to improve and transform the lives of patients.
The new company will be headquartered in the UK, including a manufacturing and R&D facility based in Gargrave, North Yorkshire, UK. Personnel from the existing Research and Development, Operations, and Sales and Marketing teams have been transferred, along with all existing brand trade marks, to Systagenix Wound Management. It is business as usual for customers while there is a new emphasis and focus within the organisation.
Steve Atkinson, CEO of Systagenix, commented, “We are totally focused on making Systagenix Wound Management the strongest and most admired wound care company. We have inherited a business with a strong heritage and outstanding pedigree providing an excellent platform for future growth. The wound care market represents substantial opportunity and with our investment plan, customer relationships and scientific and technical capabilities, Systagenix will become the driving force in the industry.”
Executive Chairman, Chris Fashek added: “We are committed to making Systagenix an outstanding success, focusing on patient needs and working with clinicians as partners to provide enhanced wound care solutions. Systagenix Wound Management may be a new name, but our people remain committed to the core value of providing advanced therapies that will improve the lives of patients. ”
Notes to Editors:
1. Established in 2001, One Equity Partners manages $8 billion of investments and commitments for J.P. Morgan Chase & Co. in direct private equity transactions. Over recent years, One Equity Partners has invested approximately $3.5 billion to acquire over thirty companies in a variety of industries including defense, chemicals, healthcare, technology and manufacturing. One Equity Partners' investment professionals are located across North America, Europe and Asia, with offices in New York, Chicago, Menlo Park, Frankfurt and Hong Kong. Visit http://www.oneequity.com/ for more information.
2. ETHICON, Inc., a Johnson & Johnson company, is a global medical device company that develops and markets surgical products for use in general surgery, wound management and women's health & urology. For more information about ETHICON, please visit www.ethicon.com.
01 Dec 2008